Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for InnoCare Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:09969 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, InnoCare Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma (HKSE:09969) has a FCF Margin % of 6.12% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on InnoCare Pharma and its competitors. According to the industry distribution chart, InnoCare Pharma ranks #237 out of 957 companies in the Biotechnology industry, placing it in the top 24.8%.
Is InnoCare Pharma's FCF Margin % too high?
InnoCare Pharma's current FCF Margin % is 6.12%. Based on the distribution chart, InnoCare Pharma ranks #237 out of 957 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCare Pharma has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #237 out of 957 companies for FCF Margin %. This places InnoCare Pharma in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on InnoCare Pharma and its competitors. InnoCare Pharma's current FCF Margin % is 6.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Pharma (HKSE:09969) is currently considered Possible Value Trap. The stock's GF Value™ is HK$21.38, compared to a current price of HK$14.27 — trading 33.3% below its estimated fair value. The current FCF Margin % is 6.12%. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For InnoCare Pharma (HKSE:09969), the current FCF Margin % is 6.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (HKSE:09969) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of HK$14.27 is trading 33.3% below its estimated GF Value™ of HK$21.38.
GuruFocus considers InnoCare Pharma to be Possible Value Trap.
Key valuation signals for HKSE:09969:
FCF Margin %: 6.12%
GF Value™: HK$21.38 vs. price of HK$14.27 (33.3% below fair value)
No single metric tells the full story. See the HKSE:09969 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score
Get the complete analysis for HKSE:09969
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09969 has been successfully added to your 
